PSMA PET‐based stereotactic body radiotherapy for locally recurrent prostate cancer after definitive first‐line therapy
The Prostate · 2023
DOI: 10.1002/pros.24592 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2023. Verfasst von Arne Gruen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department for Radiation Oncology, Campus Virchow-Klinik, Charité-Universitaetsmedizin Berlin, corporate member of Freie Universitaet Berlin, Humbold…. Hauptthemen laut MEDLINE: Radiosurgery, Prostatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Advances in prostate‐specific membrane antigen (PSMA) PET–computed tomography (CT) and magnetic resonance imaging (MRI) allow the detection and localization of exclusively local prostate‐cancer‐recurrences after definitive first‐line therapy. PSMA‐based early detection of circumscribed local recurrences followed by hypofractionated high‐precision stereotactic body radiotherapy (SBRT) might yield long‐term disease control at moderate rates of adverse effects.
Methods
Retrospective analysis of 35 patients treated for locally recurrent prostate cancer between November 2012 and December 2021 with PSMA PET‐ and MRI‐based robotic SBRT.
Results
Thirty‐five patients treated with local prostate cancer recurrence post surgery, post surgery, and adjuvant/salvage radiotherapy (RT) and after definitive RT. All but one patients had fractionated SBRT in 3–5 fractions. Median progression‐free survival (PFS) was 52.2 months for all patients and 52.2 months in the radical prostatectomy (RPE) group, 31.2 months in the RPE + RT group and not reached in the RT group. The most common event was increased urinary frequency grade 1–2. 54.3% of all patients had no acute and 79.4% no late toxicity during follow‐up.
Discussion
Our PFS of 52.2 months (RPE), 31.2 months (RPE + RT) and not reached (RT) compares favorably with published data. This method constitutes a valid alternative to morbidity‐prone invasive approaches or palliative systemic therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department for Radiation Oncology, Campus Virchow-Klinik, Charité-Universitaetsmedizin Berlin, corporate member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Berlin, Germ…
- Department for Obstetrics and Gynecology, Evangelisches Waldkrankenhaus Spandau Krankenhausbetriebs gGmbH, Berlin, Germany.
- MVZ Leipzig Strahlentherapie, Leipzig, Germany.
- Radioonkologie im Vosspalais, Berlin, Germany.
- Department for Radiation Oncology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Berlin, Germany.
- Department for Radiation Oncology, Campus Benjamin Franklin, Charité-Universitaetsmedizin Berlin, corporate member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Berlin, G…
ORCID-Profile: Arne Gruen
Zitieren
APA
Gruen, A., Tegel, K., Kluge, A., Budach, V., Zips, D., & Boehmer, D. (2023). PSMA PET‐based stereotactic body radiotherapy for locally recurrent prostate cancer after definitive first‐line therapy. The Prostate. https://doi.org/10.1002/pros.24592
Vancouver
Gruen A, Tegel K, Kluge A, Budach V, Zips D, Boehmer D. PSMA PET‐based stereotactic body radiotherapy for locally recurrent prostate cancer after definitive first‐line therapy. The Prostate. 2023. doi:10.1002/pros.24592
BibTeX
@article{Gruen2023,
author = {Gruen, Arne and Tegel, Katharina and Kluge, Anne and Budach, Volker and Zips, Daniel and Boehmer, Dirk},
title = {PSMA PET‐based stereotactic body radiotherapy for locally recurrent prostate cancer after definitive first‐line therapy},
journal = {The Prostate},
year = {2023},
doi = {10.1002/pros.24592}
}
EUVIMED